Intravitreal Injection of Triamcinolone Acetonide as Treatment of Diffuse Diabetic Macular Edema

¹Degenring R. F., ¹Söfker A., ²Kreissig I., ¹Jonas J. B.,
¹Ruprecht-Karls-Universität Heidelberg, Fakultät für klinische Medizin Mannheim, Augenklinik (Mannheim)
²Eberhard-Karls-Universität Tübingen, Universitäts-Augenklinik, Breuningerbau (Mannheim)

Purpose: To evaluate the clinical outcome of an intravitreal injection of 25 mg Triamcinolone acetonide as treatment of diffuse diabetic macular edema.
Methods: The prospective, non-randomized study included 15 eyes (15 patients) who reveived an intravitreal injection of 25 mg crystalline Triamcinolone Acetonide transconjunctivally as treatment for diffuse diabetic macular edema. Follow-up time was 7.04 ± 3.51 months. The study group was compared to a control group of 16 patients who underwent macular grid coagulation for the same disease. The control group was formed retrospectively and was matched to the study group for age, gender and preoperative visual acuity.
Results: Visual acuity was 0.08 ± 0.06 at baseline and increased significantly (p=0.004) to a maximum of 0.16 ± 0.13. Nine of ten eyes (90%) with a follow-up of more than 1 month gained in visual acuity. In the control group visual acuity did not change significantly. Intraocular pressure increased marginally significantly (p=0.063) to a mean maximum of 20.4 ± 6.6 mm Hg. At the end of the study period it decreased (p=0.063) to 17.1 ± 1.5 mm Hg. In 3 eyes (20%) intraocular pressure had to be lowered, which could be achieved by topical antiglaucomatous medication. Glaucomatous damage as determined by biomorphometry was not detected in any eye.
Conclusions: An intravitreal injection of 25 mg Triamcinolone Acetonide may be an therapeutic option for treatment of diffuse diabtic macular edema.

Copyright © Deutsche Ophthalmologische Gesellschaft, 2002. All rights reserved.

Last updated: 

Webdesign: SPALLEK.COM